Korean J Intern Med.
2022 Sep;37(5):895-905. 10.3904/kjim.2022.132.
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2533132
- DOI: http://doi.org/10.3904/kjim.2022.132
Abstract
- The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospitalization, emergency room visits, or surgery may be required, resulting in a socioeconomic burden. Great advances have been made in the development of new therapeutic options for IBD to achieve induction and maintenance remission. Nevertheless, conventional therapy is still the mainstay in the treatment of IBD. This review article provides an update on recent advances in conventional therapies, including 5-aminosalicylates, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents to treat IBD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease
- Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
- Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
- Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
- Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
